New drug shows promise against Tough-to-Treat blood cancer
NCT ID NCT04318080
Summary
This study tested an immunotherapy drug called tislelizumab in 46 people whose classical Hodgkin lymphoma had come back or stopped responding to prior treatments. The main goal was to see how many patients' tumors shrank or disappeared after receiving the drug. Participants received the treatment until their cancer progressed, they had severe side effects, or they chose to stop.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-2013, United States
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112-5550, United States
-
Monash Health
Clayton, Victoria, VIC 3168, Australia
-
University of Tennessee Medical Center
Knoxville, Tennessee, 37920-1511, United States
Conditions
Explore the condition pages connected to this study.